Tarlatamab
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Human |
| Target | DLL3 and CD3 |
| Clinical data | |
| Trade names | Imdelltra |
| Other names | AMG757; AMG-757, tarlatamab-dlle |
| AHFS/Drugs.com | Multum Consumer Information |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C4664H7139N1259O1454S34 |
| Molar mass | 105202.82 g·mol−1 |
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.
The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.
Tarlatamab was approved for medical use in the United States in May 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.